A $445 Million Bet on China's Expanding Hepatitis B Market
Aligos Therapeutics has signed an exclusive license granting Xiamen Amoytop Biotech the rights to develop and commercialize its chronic hepatitis B candidate, pevifoscorvir sodium, across Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The deal carries a total potential value of $445 million, $25 million upfront and up to $420 million in milestones tied to clinical, regulatory, and commercial progress, plus tiered, high single-digit royalties on future sales.
Aligos retains rights outside the region, giving the firm control of development and commercialization in the U.S., Europe, Japan, and South Korea. The $25 million infusion extends Aligos’s cash runway from Q3 to Q4 of 2026. For a mid-cap biotech that started the year with $77.8 million in cash, the transaction buys time without leaning on equity markets that remain harsh for small-cap issuers. A quiet survival move, but a clever one.
The deal’s structure reflects the hybrid licensing models that dominated in 2025, as U.S. biotechs sought to monetize ex-U.S. rights early while maintaining global upside. Milestone-heavy agreements like this one tie Aligos’s long-term reward to Amoytop’s execution in China’s massive HBV market, roughly 90 million people living with the infection.
Amoytop Leverages Pegbing Franchise and Deep HBV Expertise
For Amoytop, based in Fujian, acquiring Greater China rights to pevifoscorvir sodium expands an already strong hepatitis B franchise. Its pegylated interferon product Pegbing became the world’s first approved functional cure for HBV when it gained Chinese regulatory clearance in October 2025. That approval gave Amoytop both commercial credibility and manufacturing power in hepatology, a platform now being used to fold Aligos’ capsid assembly modulator (CAM‑E) into next-generation combination regimens.
Amoytop’s chairman and CEO, Sun Li, described Aligos as “at the forefront of HBV innovation” and said the partnership opens new combination options alongside Pegbing and their ongoing antisense oligonucleotide (ASO) collaboration. Aligos CEO Lawrence Blatt echoed the rationale, arguing that pairing pevifoscorvir sodium with Pegbing could support more individualized treatment paths. Both leaders clearly see synergy beyond simple licensing economics.
The logic checks out. Pegbing provides an interferon-based backbone with curative potential, while pevifoscorvir sodium aims to shut down viral persistence by blocking HBV DNA integration and shrinking the cccDNA reservoir. If the data hold up, this dual mechanism could set Amoytop ahead of multinationals such as GSK, whose own HBV functional cure candidate is approaching Chinese filings after phase 3 success. That competition is coming fast.
Amoytop’s move therefore looks preemptive, locking in a complementary antiviral to protect its market as rivals advance. The partnership also broadens Amoytop’s portfolio from interferon-only therapies into direct‑acting antivirals, positioning it as one of the few domestic firms to operate across both modalities.
A Measured Cash-Sparing Strategy for Aligos
From Aligos’s standpoint, the deal shows tight fiscal control in a punishing biotech market. While $25 million might not sound transformative, relative to Aligos’s scale it’s meaningful. Extending the cash runway to late 2026 gives management breathing room as the phase 2 B‑SUPREME trial proceeds. That study compares pevifoscorvir sodium with Gilead’s Viread (tenofovir disoproxil fumarate), a direct, high-stakes benchmark.
The next interim analysis is due in the second half of 2026, topline data in 2027. Should pevifoscorvir show a clinical edge, Aligos could seek richer ex-China licensing deals. If results fall short, at least the company will have conserved cash while letting Amoytop shoulder regional development. That’s not hedging, it’s pragmatic triage in an industry still short on patient capital.
Although milestone payments supply upside, most of the $445 million headline sits behind contingencies. That risk-sharing setup is typical for Asia-focused licensing, but investors will track how fast Amoytop initiates local trials and files for regulatory review. Closing still depends on Amoytop shareholder approval within 30 days, a routine vote given the strategic logic.
Ultimately, Aligos chose partnership over infrastructure. Avoid immediate dilution, extend cash, and align success with a proven domestic player. It’s the same pattern other mid-stage U.S. biotechs have followed to stay alive through 2025‑2026 when capital raises became borderline punitive.
Competitive and Regulatory Crosscurrents in HBV Innovation
Chronic hepatitis B remains one of the biggest unmet medical challenges, especially in Asia where prevalence and mortality remain high. Existing nucleos(t)ide analogs can suppress replication but do not eliminate the cccDNA reservoir, leaving chronic carriers susceptible to liver cancer. That limitation drives ongoing R&D across multiple approaches: capsid modulators, ASOs, siRNAs, and immune-based treatments.
Aligos’s candidate fits into the capsid assembly modulator category, one being pursued by several mid-stage competitors. Its dual mechanism offers a theoretical path toward functional cure, but that claim awaits human proof. The head-to-head against tenofovir should generate unusually clean comparative data for regulators and payers, a rare design choice in this field.
Amoytop’s prior experience with Pegbing means it already has the infrastructure and regulatory relationships to move quickly. Chinese authorities have warmed to combination regimens pairing direct‑acting antivirals with immunotherapies, especially since Pegbing’s approval. If pevifoscorvir integrates safely with interferon or ASO components, Amoytop could have a combination product ready before Western entrants arrive.
For international investors watching cross‑border deal flow, this transaction highlights the new balance: Western innovation matched with Asian commercialization. Chinese hepatology firms have turned into active acquirers of Western science. That dynamic, tracked by RxInfo.ai, could reshape pricing, reimbursement, and competitive barriers across HBV treatments in the next few years.
Signals for 2026: Funding Discipline and Regional Partnerships
If the pattern continues, 2026 will see more region-specific, capital-efficient deals as smaller biotechs sell territorial rights instead of raising equity. The Aligos-Amoytop construct, modest cash up front, milestone-heavy backend, split development, represents today’s midpoint between capital scarcity in the West and confidence rising in China’s infectious disease sector.
Observers will watch whether Aligos repeats this model in other HBV-heavy markets like Japan or South Korea, where healthcare systems and reimbursement frameworks differ. For Amoytop, the nearer-term question is speed: how fast can it start trials combining pevifoscorvir sodium with Pegbing and the partnered ASO therapy? China’s NMPA has fast-tracked reviews for homegrown antiviral combinations, meaning local timelines could easily narrow once filings land.
From an investor’s view, the economics and sequencing of this deal, limited upfront, milestone-weighted, royalty-linked, define the current biotech reality. Whether that becomes value-accretive depends entirely on performance. Aligos must deliver credible data; Amoytop must deliver regulatory progress. If both do, the $25 million bridge financing of 2026 could evolve into a $445 million commercial outcome. Or not. Analysts will be watching either way.
